Esperance Pharmaceuticals, Inc. is a company involved in developing anticancer drugs within the biopharmaceutical industry. Their offerings include a class of drugs designed to kill cancer cells while sparing normal cells, with an emphasis on treating cells resistant to traditional chemotherapy. Esperance Pharmaceuticals primarily targets the oncology sector, particularly in ovarian and breast cancer. It was founded in 2005 and is based in Houston, Texas.

Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.

AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.

OcuNexus Therapeutics focuses on the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 hemichannel, which is responsible for inflammasome-mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Radio Therapeutics Corporation develops and manufactures radiofrequency-based therapeutic devices for the destruction of various forms of soft tissue tumors. RTC markets the Radiofrequency Ablation System, which uses radiofrequency energy to selectively destroy undesirable soft tissue. The technology is based on hyperthermia (overheating) of the tumor to destroy it with the use of a specially designed probe which is inserted into the tumor. The probe architecture is the core of the technology and permits a localized application of radio-frequency energy. The system is used by radiologists and surgical oncologists for the ablation of nonresectable (inoperable) liver lesions.